Abbott Pulls Trifecta Heart Valves off the Market Due to Early Deterioration

Because of the potential risk of early structural valve deterioration, the FDA has sent notice about Abbott’s decision to stop selling and distributing Trifecta aortic surgical heart valves in the United States. The FDA recommends that healthcare providers be aware of the risk of SVD with Trifecta valves, discuss risk with patients, and monitor patients who have undergone implantation with Trifecta valves.Because of the potential risk of early structural valve deterioration, the FDA has sent notice about Abbott’s decision to stop selling and distributing Trifecta aortic surgical heart valves in the United States. The FDA recommends that healthcare providers be aware of the risk of SVD with Trifecta valves, discuss risk with patients, and monitor patients who have undergone implantation with Trifecta valves.